Literature DB >> 29777060

Protease-activated receptor 1 inhibits cholesterol efflux and promotes atherogenesis via cullin 3-mediated degradation of the ABCA1 transporter.

Somasundaram Raghavan1, Nikhlesh K Singh1, Arul M Mani1, Gadiparthi N Rao2.   

Abstract

Although signaling of thrombin via its receptor protease-activated receptor 1 (Par1) is known to occur in atherothrombosis, its link to the actual pathogenesis of this condition is less clear. To better understand the role of thrombin-Par1 signaling in atherosclerosis, here we have studied their effects on cellular cholesterol efflux in mice. We found that by activating Par1 and cullin 3-mediated ubiquitination and degradation of ABC subfamily A member 1 (ABCA1), thrombin inhibits cholesterol efflux in both murine macrophages and smooth muscle cells. Moreover, disruption of the Par1 gene rescued ABCA1 from Western diet-induced ubiquitination and degradation and restored cholesterol efflux in apolipoprotein E-deficient (ApoE-/-) mice. Similarly, the Par1 deletion diminished diet-induced atherosclerotic lesions in the ApoE-/- mice. These observations for the first time indicate a role for thrombin-Par1 signaling in the pathogenesis of diet-induced atherosclerosis. We identify cullin 3 as a cullin-RING ubiquitin E3 ligase that mediates ABCA1 ubiquitination and degradation and thereby inhibits cholesterol efflux. Furthermore, compared with peripheral blood mononuclear cells (PBMCs) from ApoE-/- mice, the PBMCs from ApoE-/-:Par1-/- mice exhibited decreased trafficking to inflamed arteries of Western diet-fed ApoE-/- mice. This finding suggested that besides inhibiting cholesterol efflux, thrombin-Par1 signaling also plays a role in the recruitment of leukocytes during diet-induced atherogenesis. Based on these findings, we conclude that thrombin-Par1 signaling appears to contribute to the pathogenesis of atherosclerosis by impairing cholesterol efflux from cells and by recruiting leukocytes to arteries.
© 2018 Raghavan et al.

Entities:  

Keywords:  ABC transporter; atherosclerosis; cholesterol; macrophage; signal transduction

Mesh:

Substances:

Year:  2018        PMID: 29777060      PMCID: PMC6036195          DOI: 10.1074/jbc.RA118.003491

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  Human cytomegalovirus increases modified low density lipoprotein uptake and scavenger receptor mRNA expression in vascular smooth muscle cells.

Authors:  Y F Zhou; E Guetta; Z X Yu; T Finkel; S E Epstein
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

2.  Cyclic strain increases protease-activated receptor-1 expression in vascular smooth muscle cells.

Authors:  K T Nguyen; S R Frye; S G Eskin; C Patterson; M S Runge; L V McIntire
Journal:  Hypertension       Date:  2001-11       Impact factor: 10.190

Review 3.  Targeting factor Xa and thrombin: impact on coagulation and beyond.

Authors:  Charles T Esmon
Journal:  Thromb Haemost       Date:  2013-12-12       Impact factor: 5.249

4.  Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis.

Authors:  F Mach; U Schönbeck; G K Sukhova; T Bourcier; J Y Bonnefoy; J S Pober; P Libby
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

5.  Syndecan-4 is required for thrombin-induced migration and proliferation in human vascular smooth muscle cells.

Authors:  Bernhard H Rauch; Esther Millette; Richard D Kenagy; Guenter Daum; Jens W Fischer; Alexander W Clowes
Journal:  J Biol Chem       Date:  2005-02-24       Impact factor: 5.157

6.  Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.

Authors:  Anna K Kopec; Nikita Joshi; Keara L Towery; Karen M Kassel; Bradley P Sullivan; Matthew J Flick; James P Luyendyk
Journal:  J Pharmacol Exp Ther       Date:  2014-08-19       Impact factor: 4.030

Review 7.  Inflammation, obesity, and thrombosis.

Authors:  Fahumiya Samad; Wolfram Ruf
Journal:  Blood       Date:  2013-10-03       Impact factor: 22.113

8.  The KLHL12-Cullin-3 ubiquitin ligase negatively regulates the Wnt-beta-catenin pathway by targeting Dishevelled for degradation.

Authors:  Stephane Angers; Chris J Thorpe; Travis L Biechele; Seth J Goldenberg; Ning Zheng; Michael J MacCoss; Randall T Moon
Journal:  Nat Cell Biol       Date:  2006-03-19       Impact factor: 28.824

9.  Novel role of proline-rich nonreceptor tyrosine kinase 2 in vascular wall remodeling after balloon injury.

Authors:  Ravisekhar Gadepalli; Nikhlesh K Singh; Venkatesh Kundumani-Sridharan; Mark R Heckle; Gadiparthi N Rao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-08-23       Impact factor: 8.311

Review 10.  Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses.

Authors:  Laurent Yvan-Charvet; Nan Wang; Alan R Tall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10-01       Impact factor: 8.311

View more
  14 in total

1.  Protease Activity in Vascular Disease.

Authors:  Megan A Slack; Scott M Gordon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-25       Impact factor: 8.311

Review 2.  Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases.

Authors:  Jens J Posma; Steven P Grover; Yohei Hisada; A Phillip Owens; Silvio Antoniak; Henri M Spronk; Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

3.  Exosome-Mediated Transfer of Anti-miR-33a-5p from Transduced Endothelial Cells Enhances Macrophage and Vascular Smooth Muscle Cell Cholesterol Efflux.

Authors:  Alexis Stamatikos; Ethan Knight; Lucia Vojtech; Lianxiang Bi; Bradley K Wacker; Chongren Tang; David A Dichek
Journal:  Hum Gene Ther       Date:  2020-01-16       Impact factor: 5.695

4.  Xiaoyaosan prevents atherosclerotic vulnerable plaque formation through heat shock protein/glucocorticoid receptor axis-mediated mechanism.

Authors:  Wenjun Fu; Mingtai Chen; Lijun Ou; Tao Li; Xiao Chang; Ruolan Huang; Jian Zhang; Zhong Zhang
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

5.  NFATc1-E2F1-LMCD1-Mediated IL-33 Expression by Thrombin Is Required for Injury-Induced Neointima Formation.

Authors:  Suresh Govatati; Prahalathan Pichavaram; Jagadeesh Janjanam; Baolin Zhang; Nikhlesh K Singh; Arul M Mani; James G Traylor; A Wayne Orr; Gadiparthi N Rao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-06       Impact factor: 8.311

Review 6.  The emerging role of sorting nexins in cardiovascular diseases.

Authors:  Jian Yang; Van Anthony M Villar; Selim Rozyyev; Pedro A Jose; Chunyu Zeng
Journal:  Clin Sci (Lond)       Date:  2019-03-15       Impact factor: 6.124

7.  Regression of Atherosclerosis in ApoE-/- Mice Via Modulation of Monocyte Recruitment and Phenotype, Induced by Weekly Dosing of a Novel "Cytotopic" Anti-Thrombin Without Prolonged Anticoagulation.

Authors:  Daxin Chen; Ke Li; Sam Festenstein; Julieta Karegli; Hannah Wilkinson; Hugh Leonard; Lin-Lin Wei; Ning Ma; Min Xia; Henry Tam; Jian-An Wang; Qingbo Xu; John H McVey; Richard A G Smith; Anthony Dorling
Journal:  J Am Heart Assoc       Date:  2020-07-02       Impact factor: 5.501

Review 8.  Targeting Platelet in Atherosclerosis Plaque Formation: Current Knowledge and Future Perspectives.

Authors:  Lei Wang; Chaojun Tang
Journal:  Int J Mol Sci       Date:  2020-12-21       Impact factor: 5.923

9.  PAR-1 signaling on macrophages is required for effective in vivo delayed-type hypersensitivity responses.

Authors:  Hannah Wilkinson; Hugh Leonard; Daxin Chen; Toby Lawrence; Michael Robson; Pieter Goossens; John H McVey; Anthony Dorling
Journal:  iScience       Date:  2021-01-05

10.  miR-155-5p predictive role to decelerate foam cell atherosclerosis through CD36, VAV3, and SOCS1 pathway.

Authors:  Ermin Rachmawati; Djanggan Sargowo; M Saifur Rohman; Nashi Widodo; Umi Kalsum
Journal:  Noncoding RNA Res       Date:  2021-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.